Alessandro Vannini elected EMBO member
The European Molecular Biology Organisation (EMBO) is an organization of more than 2,000 leading researchers that promotes excellence in the life sciences in Europe and beyond. Every year outstanding researchers around the world are given the opportunity to join the community as EMBO members. This is a lifelong honour for distinguished scientists who have made important contributions to the life sciences over the course of their careers.
Among the 69 new EMBO members announced today is Alessandro Vannini, Head of the Structural Biology Research Centre at Human Technopole.
Alessandro was the first Head of Research Centre and Group Leader to join Human Technopole in September 2019, when the institute was still in the very early stages of development. He moved to Milan from London where he previously worked as Principal Investigator and Deputy Head of Division at the Institute of Cancer Research in London. Over the past four years he has built up the Structural Biology Research Centre, which now includes five research groups and 45 active researchers.
When hearing about his election as EMBO member, Alessandro noted: “What an incredible honour to be elected EMBO Member and become a part of such an inspirational group of scientists. I am very grateful for EMBO support throughout the years, from being an EMBO Postdoctoral fellow to then becoming an EMBO Young Investigator. These programmes played a truly important role in shaping my career as a scientist. Being elected an EMBO Member now means coming full circle and I am looking forward to being part of this fantastic community.”
About EMBO membership
EMBO members can actively participate in EMBO’s initiatives by serving on the organisation’s Council, committees and editorial boards, participating in the evaluation of applications for EMBO funding, acting as mentors to young scientists in our community, and advising on key activities. EMBO members also have the privilege to nominate and elect candidates for EMBO membership, for Council and for the EMBO Gold Medal.
Learn more: www.embo.org/members.html
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.